LiveLive
SPX7585.7300-1.1400%IXIC25981.5700-1.6600%FTSE10719.39000.4600%GOLD4351.90000.5800%SILVER64.80000.2200%PLATINUM1788.00000.0600%PALLADIUM1336.00000.3000%BRENT107.58002.8400%DJI52093.1100-1.3100%WTI103.67003.6200%NDX28937.8400-1.9300%NATGAS2.93003.4600%BTC75955.0000-1.4200%RUT2870.2800-3.0400%VIX16.9800-4.8200%ETH2405.2100-3.1900%DAX25421.7900-0.6000%BNB711.2500-1.1300%XRP1.2900-8.0500%CAC408113.4600-0.0400%NKY63923.0000-2.0700%DOGE0.0800-3.3000%HSI24713.7800-2.2200%ADA0.1900-5.3200%NIFTY23217.6000-1.1100%SOL97.2700-3.6100%AAPL331.34004.7800%SENSEX74336.4500-0.7600%MSFT497.12000.6400%TASI10790.71000.0800%IBOV186502.6400-0.4600%GOOGL344.98001.9600%TSLA356.5800-3.1500%MERVAL3079778.80000.1200%TSX35582.0700-1.5000%USD/PKR277.15003.1000%ASX2008696.5000-2.4100%EUR/PKR320.19002.3700%STI5635.4100-1.6400%GBP/PKR373.8600-0.2300%SAR/PKR73.87000.0300%FBMKLCI1679.2100-1.5400%AED/PKR75.54000.0800%SET1562.7300-1.0100%KOSPI6717.9700-4.7300%USD/EUR0.87000.8300%TWSE45848.9000-2.3300%GASOLINE3.2200-2.5600%HEATOIL5.03001.4300%COPPER6.51000.5600%WHEAT731.50003.4700%CORN536.50005.1400%SOYBEANS1329.50003.8500%COFFEE282.8000-9.8400%COCOA5959.00000.4400%SUGAR18.66002.8100%COTTON84.46002.5200%TRX0.3300-1.1600%AVAX7.2600-3.4600%LINK10.8200-4.9600%DOT0.9600-3.4400%LTC50.6900-3.5600%SHIB0.0000-5.3500%TON1.3100-2.1400%XLM0.1800-9.8800%HBAR0.0700-4.1100%SUI0.6900-2.8800%APT0.5300-8.3400%UNI6.3100-5.9800%PEPE0.0000-2.7100%NEAR2.42000.9500%ARB0.160017.7700%OP0.0900-6.5400%MATIC0.13000.0000%INJ5.4000-9.8300%FIL0.8100-9.2300%ICP2.5000-3.0500%STX0.00000.0000%ETC7.1800-3.2400%ALGO0.0900-7.0900%VET0.0100-1.8900%THETA0.1800-4.2200%FTM0.03000.0000%SAND0.0300-4.7700%MANA0.0700-2.0800%AXS0.9000-3.1200%GALA0.0000-4.1400%CRV0.3100-7.5600%MKR1371.1200-5.0500%AMZN248.4200-3.3300%NVDA212.1700-6.0100%META670.24009.2500%NFLX77.90001.4700%AMD504.2000-0.3000%AVGO339.2700-7.9500%JPM352.4900-0.2900%V375.62001.8900%MA573.27000.4200%XOM169.32005.3900%CVX217.77003.8000%KO88.71000.4000%PEP135.5000-2.1300%DIS106.42001.2900%BA209.6900-0.4900%BABA109.3400-2.9500%JD27.0900-2.1300%PDD78.0800-2.0900%NIO3.6000-5.0100%SPY757.3900-1.1200%QQQ704.5400-1.9200%DIA521.2300-1.2900%IWM285.1400-3.2300%GLD394.1500-1.3900%SLV57.5300-3.1000%TLT80.7100-1.8100%HYG78.3800-0.9400%LQD104.2800-1.1400%XLF56.8500-0.7900%XLK183.7400-2.2000%XLE65.93001.7900%XLV167.66000.3200%SMH542.1100-5.5100%ARKK83.4900-3.0100%EEM65.7600-4.4600%IBIT43.1100-2.8800%QAR/PKR76.10000.3100%INR/PKR2.8900-1.5700%JPY/PKR1.79000.6800%CAD/PKR199.2200-0.5700%AUD/PKR197.9100-0.9200%NZD/PKR159.7800-2.0000%MYR/PKR67.8600-1.0200%THB/PKR8.3400-0.9300%EUR/USD1.1500-0.8200%GBP/USD1.3500-0.6100%USD/JPY155.13001.0100%USD/CHF0.82001.1400%AUD/USD0.7100-1.2000%USD/CAD1.39000.9300%NZD/USD0.5800-1.4400%USD/INR95.94000.8700%USD/CNY6.7100-0.0500%USD/HKD7.84000.0200%USD/SGD1.27000.7300%USD/KRW1366.98002.0800%USD/TRY48.64000.3200%USD/ZAR16.27001.4600%USD/MXN17.14001.4800%USD/BRL5.15000.8900%USD/RUB84.4500-0.6500%USD/NGN1323.78000.0500%USD/EGP52.17001.8700%USD/KES129.55000.8700%USD/BDT123.65003.6700%USD/LKR331.08003.7900%USD/IDR17690.00001.0800%USD/THB33.25001.0000%USD/MYR4.09000.5000%USD/PHP62.67000.3300%USD/VND25958.00000.2100%USD/ILS3.03000.2700%USD/SAR3.76003.2900%USD/AED3.67000.0400%USD/QAR3.6400-0.2000%USD/KWD0.31000.0000%USD/BHD0.38000.0000%USD/OMR0.39000.4700%SPX7585.7300-1.1400%IXIC25981.5700-1.6600%FTSE10719.39000.4600%GOLD4351.90000.5800%SILVER64.80000.2200%PLATINUM1788.00000.0600%PALLADIUM1336.00000.3000%BRENT107.58002.8400%DJI52093.1100-1.3100%WTI103.67003.6200%NDX28937.8400-1.9300%NATGAS2.93003.4600%BTC75955.0000-1.4200%RUT2870.2800-3.0400%VIX16.9800-4.8200%ETH2405.2100-3.1900%DAX25421.7900-0.6000%BNB711.2500-1.1300%XRP1.2900-8.0500%CAC408113.4600-0.0400%NKY63923.0000-2.0700%DOGE0.0800-3.3000%HSI24713.7800-2.2200%ADA0.1900-5.3200%NIFTY23217.6000-1.1100%SOL97.2700-3.6100%AAPL331.34004.7800%SENSEX74336.4500-0.7600%MSFT497.12000.6400%TASI10790.71000.0800%IBOV186502.6400-0.4600%GOOGL344.98001.9600%TSLA356.5800-3.1500%MERVAL3079778.80000.1200%TSX35582.0700-1.5000%USD/PKR277.15003.1000%ASX2008696.5000-2.4100%EUR/PKR320.19002.3700%STI5635.4100-1.6400%GBP/PKR373.8600-0.2300%SAR/PKR73.87000.0300%FBMKLCI1679.2100-1.5400%AED/PKR75.54000.0800%SET1562.7300-1.0100%KOSPI6717.9700-4.7300%USD/EUR0.87000.8300%TWSE45848.9000-2.3300%GASOLINE3.2200-2.5600%HEATOIL5.03001.4300%COPPER6.51000.5600%WHEAT731.50003.4700%CORN536.50005.1400%SOYBEANS1329.50003.8500%COFFEE282.8000-9.8400%COCOA5959.00000.4400%SUGAR18.66002.8100%COTTON84.46002.5200%TRX0.3300-1.1600%AVAX7.2600-3.4600%LINK10.8200-4.9600%DOT0.9600-3.4400%LTC50.6900-3.5600%SHIB0.0000-5.3500%TON1.3100-2.1400%XLM0.1800-9.8800%HBAR0.0700-4.1100%SUI0.6900-2.8800%APT0.5300-8.3400%UNI6.3100-5.9800%PEPE0.0000-2.7100%NEAR2.42000.9500%ARB0.160017.7700%OP0.0900-6.5400%MATIC0.13000.0000%INJ5.4000-9.8300%FIL0.8100-9.2300%ICP2.5000-3.0500%STX0.00000.0000%ETC7.1800-3.2400%ALGO0.0900-7.0900%VET0.0100-1.8900%THETA0.1800-4.2200%FTM0.03000.0000%SAND0.0300-4.7700%MANA0.0700-2.0800%AXS0.9000-3.1200%GALA0.0000-4.1400%CRV0.3100-7.5600%MKR1371.1200-5.0500%AMZN248.4200-3.3300%NVDA212.1700-6.0100%META670.24009.2500%NFLX77.90001.4700%AMD504.2000-0.3000%AVGO339.2700-7.9500%JPM352.4900-0.2900%V375.62001.8900%MA573.27000.4200%XOM169.32005.3900%CVX217.77003.8000%KO88.71000.4000%PEP135.5000-2.1300%DIS106.42001.2900%BA209.6900-0.4900%BABA109.3400-2.9500%JD27.0900-2.1300%PDD78.0800-2.0900%NIO3.6000-5.0100%SPY757.3900-1.1200%QQQ704.5400-1.9200%DIA521.2300-1.2900%IWM285.1400-3.2300%GLD394.1500-1.3900%SLV57.5300-3.1000%TLT80.7100-1.8100%HYG78.3800-0.9400%LQD104.2800-1.1400%XLF56.8500-0.7900%XLK183.7400-2.2000%XLE65.93001.7900%XLV167.66000.3200%SMH542.1100-5.5100%ARKK83.4900-3.0100%EEM65.7600-4.4600%IBIT43.1100-2.8800%QAR/PKR76.10000.3100%INR/PKR2.8900-1.5700%JPY/PKR1.79000.6800%CAD/PKR199.2200-0.5700%AUD/PKR197.9100-0.9200%NZD/PKR159.7800-2.0000%MYR/PKR67.8600-1.0200%THB/PKR8.3400-0.9300%EUR/USD1.1500-0.8200%GBP/USD1.3500-0.6100%USD/JPY155.13001.0100%USD/CHF0.82001.1400%AUD/USD0.7100-1.2000%USD/CAD1.39000.9300%NZD/USD0.5800-1.4400%USD/INR95.94000.8700%USD/CNY6.7100-0.0500%USD/HKD7.84000.0200%USD/SGD1.27000.7300%USD/KRW1366.98002.0800%USD/TRY48.64000.3200%USD/ZAR16.27001.4600%USD/MXN17.14001.4800%USD/BRL5.15000.8900%USD/RUB84.4500-0.6500%USD/NGN1323.78000.0500%USD/EGP52.17001.8700%USD/KES129.55000.8700%USD/BDT123.65003.6700%USD/LKR331.08003.7900%USD/IDR17690.00001.0800%USD/THB33.25001.0000%USD/MYR4.09000.5000%USD/PHP62.67000.3300%USD/VND25958.00000.2100%USD/ILS3.03000.2700%USD/SAR3.76003.2900%USD/AED3.67000.0400%USD/QAR3.6400-0.2000%USD/KWD0.31000.0000%USD/BHD0.38000.0000%USD/OMR0.39000.4700%
GuruAlpha
GuruAlpha

ਪੜਚੋਲ

ਹੋਮਟੂਲਸ

ਭਾਸ਼ਾ

Senate Grills Trump Health Nominees as Third Surgeon General Choice Faces Scrutiny
World

Senate Grills Trump Health Nominees as Third Surgeon General Choice Faces Scrutiny

Senate lawmakers grilled President Donald Trump's top health choices, focusing on Dr. Nicole Saphier as political battles over public health leadership intensify.

GA

GuruAlpha News Desk

GuruAlpha News Desk

4 min read
ShareXFacebookWhatsApp

On September 16, 2026, the Senate Committee on Health, Education, Labor, and Pensions convened to examine three high-profile Trump administration health nominees. At the center of the confirmation battle stands Dr. Nicole Saphier, the president's third choice for U.S. Surgeon General, following months of political turmoil surrounding public health leadership and policy direction.

A High-Stakes Confirmation Hearing on Capitol Hill

The Senate Health, Education, Labor, and Pensions (HELP) Committee opened questioning on Wednesday, zeroing in on the credentials, past statements, and administrative philosophies of three key health nominees. The hearing highlighted deep ideological divides between lawmakers demanding strict adherence to established scientific consensus and administration allies seeking a structural overhaul of federal health agencies.

Dr. Nicole Saphier, a board-certified radiologist and frequent media commentator, faces an uphill battle to secure approval. Her nomination follows two previous choices by President Donald Trump who withdrew or failed to secure sufficient support among Senate members. Lawmakers pressed Saphier on her plans for the U.S. Public Health Service Commissioned Corps and her personal stances on childhood immunization schedules, institutional transparency, and emergency response protocols.

During intense exchanges, committee members examined Saphier's historical commentary on public health mandates. Democratic senators focused on whether her past broadcast statements aligned with rigorous epidemiological data, while Republican members praised her willingness to challenge bureaucracy and advocate for personal medical autonomy.

The Fragile State of Top Federal Public Health Leadership

The position of Surgeon General—often called "America's Doctor"—holds immense symbolic and advisory weight. While the role lacks direct regulatory authority compared to the leadership of the Food and Drug Administration (FDA) or the Centers for Disease Control and Prevention (CDC), the Surgeon General commands the bully pulpit to shape national health priorities, issue public advisories, and direct thousands of public health officers.

The vacancy at the helm of the Surgeon General's office has stretched over critical administrative quarters. The repeated failure to confirm a candidate underscores the ongoing friction between the White House and Capitol Hill regarding federal public health strategy . Saphier's predecessors surrendered their bids after congressional aides uncovered past organizational conflicts and controversial public statements that threatened to stall broader legislative priorities.

Healthcare institutions and medical associations are tracking these proceedings closely. The lack of permanent leadership at top health posts leaves crucial initiatives unstaffed and policy decisions in limbo. Professional bodies including the American Medical Association have emphasized that stable, scientifically grounded leadership remains vital for maintaining public confidence in federal health directives.

Navigating Partisan Divides on Public Health Strategy

Wednesday's hearing extended beyond Saphier to encompass two other critical appointments within the Department of Health and Human Services (HHS). Lawmakers challenged the nominees on rising national health expenditures, chronic disease prevention programs, and the allocation of research funding for major federal medical studies.

Opposing senators raised concerns about potential political interference in clinical guidance. "The public relies on federal health leadership to deliver clear, uncompromised, and data-driven guidance," noted one senior committee member during opening remarks. Nominees countered by asserting their commitment to evidence-based policy while advocating for administrative reforms designed to make agencies more accountable to elected leadership.

For global public health partners and international medical bodies, the leadership trajectory in Washington carries substantial operational weight. American health agencies establish clinical standards, direct international research funds, and coordinate global response networks. Prolonged confirmation battles signal potential shifts in federal research funding priorities and international health diplomacy .

The HELP Committee is expected to schedule a formal vote on Saphier and her fellow nominees following a period for submitted written questions. With a narrow majority in the Senate chamber, the White House must secure nearly unanimous party support to advance Saphier toward full confirmation on the Senate floor.

Frequently Asked Questions

Who is Dr. Nicole Saphier and what role has she been nominated for?

Dr. Nicole Saphier is a board-certified radiologist and media medical contributor nominated by President Donald Trump as U.S. Surgeon General. She represents his third attempt to fill the nation's top public health advocate post.

Why did the Senate HELP Committee hold confirmation hearings for Trump's health picks?

The Senate HELP Committee convened to evaluate three administration health nominees on their credentials, public health strategies, and operational philosophies. Lawmakers pressed the candidates on vaccine oversight, agency transparency, and scientific integrity.

Why had President Trump's previous nominations for Surgeon General failed?

President Trump's prior two candidates withdrew from consideration after encountering opposition on Capitol Hill over administrative controversies and conflicting public policy stances, leaving the post vacant for months.

Source:npr.org
Share this story
ShareXFacebookWhatsApp
GA

GuruAlpha News Desk

The GuruAlpha News team delivers accurate, timely coverage of breaking news, markets, technology, and lifestyle — in English and Urdu.

NewsBreaking

Related Stories

All World

More Stories

Home